Tag: biosimilar approval
Biosimilar Approval: How the FDA Reviews Biologic Alternatives in 2026
The FDA's 2025 guidance streamlines biosimilar approval by replacing costly clinical trials with advanced analytical data, accelerating access to lower-cost biologic alternatives for cancer, arthritis, and diabetes. Learn how the process works and what's still holding it back.
view morerecent posts
Team-based care transforms how generic drugs are prescribed by bringing together doctors, pharmacists, and nurses to improve safety, adherence, and cost savings - especially for patients with multiple chronic conditions.
Published ON: 18 FebGeneric drugs cost far less than brand-name drugs not because ingredients are cheaper, but because labor costs are structured differently. Learn how scale, regulation, and global production shape the real cost of your prescriptions.
Published ON: 9 FebEdema in CKD is caused by fluid buildup from failing kidneys. Managing it requires a three-part strategy: the right diuretics, strict salt restriction, and compression therapy. Learn how each works-and how to use them safely.
Published ON: 7 FebHyponatremia and hypernatremia are common, dangerous complications in kidney disease. Learn how sodium imbalances happen, why standard treatments fail, and what actually works to protect your health.
Published ON: 8 FebDiscover how the FDA maintains strict quality standards for generic drugs through cGMP regulations, unannounced inspections, and rigorous testing. Learn about the five key control areas, global comparisons, and real-world impact on drug safety and affordability.
Published ON: 4 Feb